Real-World Treatment Sequencing, Toxicities, Health Utilities, and Survival Outcomes in Patients with Advanced ALK-Rearranged Non-Small-Cell Lung Cancer

克里唑蒂尼 医学 肺癌 内科学 肿瘤科 癌症 恶性胸腔积液
作者
Sabine Schmid,Sierra Cheng,Simren Chotai,Miguel García-Pardo,Luna Jia Zhan,Katrina Hueniken,Karmugi Balaratnam,Khaleeq Khan,Devalben Patel,Benjamin Grant,Roula Raptis,M. Catherine Brown,Wei Xu,Patrick M. Moriarty,Frances A. Shepherd,Adrian G. Sacher,Natasha B. Leighl,Penelope A. Bradbury,Geoffrey Liu
出处
期刊:Clinical Lung Cancer [Elsevier BV]
卷期号:24 (1): 40-50 被引量:23
标识
DOI:10.1016/j.cllc.2022.09.007
摘要

This real-world analysis describes treatment patterns, sequencing and clinical effectiveness, toxicities, and health utility outcomes in advanced-stage, incurable ALK-positive NSCLC patients across five different ALK-TKIs.Clinicodemographic, treatment, and toxicity data were collected retrospectively in patients with advanced-stage ALK-positive NSCLC at Princess Margaret Cancer Centre. Patient-reported symptoms, toxicities, and health utilities were collected prospectively.Of 148 ALK-positive NSCLC patients seen July 2009-May 2021, median age was 58.9 years; 84 (57%) were female; 112 (76%) never-smokers; 54 (47%) Asian and 40 (35%) white; 139 (94%) received at least one ALK-TKI: crizotinib (n = 74; 54%) and alectinib (n = 61; 44%) were administered mainly as first-line ALK-TKI, ceritinib, brigatinib and lorlatinib were administered primarily after previous ALK-TKI failure. Median overall survival (OS) was 54.0 months; 31 (21%) patients died within two years of advanced-stage diagnosis. Treatment modifications were observed in 35 (47%) patients with crizotinib, 19 (61%) with ceritinib, 41 (39%) with alectinib, 9 (41%) with brigatinib and 8 (30%) with lorlatinib. Prevalence of dose modifications and self-reported toxicities were higher with early versus later generation ALK-TKIs (P<.05). The presence of early treatment modification was not negatively associated with progression-free survival (PFS) and OS analyses.Serial ALK-TKI sequencing approaches are viable therapeutic options that can extend quality of life and quantity-of-life, though a fifth of patients died within two years. No best single sequencing approach could be determined. Clinically relevant toxicities occurred across all ALK-TKIs. Treatment modifications due to toxicity may not necessarily compromise outcomes, allowing multiple approaches to deal with ALK-TKI toxicities.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
zhangyupei发布了新的文献求助30
刚刚
热心市民小红花完成签到,获得积分0
刚刚
长言完成签到 ,获得积分10
刚刚
sljzhangbiao11完成签到,获得积分10
刚刚
疯狂加载ing的应助被时平谊采纳,获得10
1秒前
Hello的应助被ykyin采纳,获得10
1秒前
1秒前
2秒前
AK完成签到,获得积分20
2秒前
2秒前
BUILUE关注了科研通微信公众号
2秒前
yjh完成签到,获得积分10
3秒前
yme7o完成签到,获得积分10
3秒前
黎秣完成签到,获得积分10
3秒前
小宇神男人完成签到,获得积分20
3秒前
lnvvl完成签到 ,获得积分10
3秒前
张米完成签到,获得积分10
3秒前
熏风完成签到,获得积分10
3秒前
实验室发布了新的文献求助10
3秒前
江波完成签到,获得积分10
3秒前
哎哟喂完成签到,获得积分10
3秒前
爆米花的应助被111采纳,获得10
4秒前
迪迪张发布了新的文献求助10
4秒前
SciGPT的应助被潆星采纳,获得10
4秒前
www完成签到 ,获得积分10
4秒前
Akim的应助被LEETHEO采纳,获得10
5秒前
5秒前
5秒前
5秒前
zy完成签到 ,获得积分10
5秒前
orixero的应助被焦糖布丁采纳,获得10
6秒前
zyy发布了新的文献求助10
6秒前
Orange的应助被闪闪晓绿采纳,获得10
6秒前
6秒前
野性的飞机完成签到 ,获得积分10
6秒前
SYY完成签到,获得积分10
6秒前
华赛发布了新的文献求助10
6秒前
Chambray发布了新的文献求助50
6秒前
6秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180617
求助须知:如何正确求助?哪些是违规求助? 9570702
关于积分的说明 21813868
捐赠科研通 7776860
什么是DOI,文献DOI怎么找? 3433294
关于科研通互助平台的介绍 2557571
邀请新用户注册赠送积分活动 2479253